Zum Inhalt springen
Technische Universität München

Publications

  1. "Macrophage migration inhibitory factor (MIF) and its homolog D-dopachrome tautomerase (D-DT) are significant promotors of UVB- but not chemically induced non-melanoma skin cancer."
    Huth S, Huth L, Heise R, Marquardt Y, Lopopolo L, Piecychna M, Boor P, Fingerle-Rowson G, Kapurniotu A, Yazdi AS, Bucala R, Bernhagen J, Baron JM. Sci Rep. 2023 Jul 18;13(1):11611. doi: 10.1038/s41598-023-38748-9.
  2. "Pathways linking aging and atheroprotection in Mif-deficient atherosclerotic mice."
    Krammer C, Yang B, Reichl S, Besson-Girard S, Ji H, Bolini V, Schulte C, Noels H, Schlepckow K, Jocher G, Werner G, Willem M, El Bounkari O, Kapurniotu A, Gokce O, Weber C, Mohanta S, Bernhagen J. FASEB J. 2023 Mar;37(3):e22752. doi: 10.1096/fj.202200056R.
  3. "Lasso-grafted designer cytokines."
    Kapurniotu A, Bernhagen J. Nat Biomed Eng. 2022 Nov 24. doi: 10.1038/s41551-022-00974-3.
  4. "Heterocomplexes between the atypical chemokine MIF and the CXC-motif chemokine CXCL4L1 regulate inflammation and thrombus formation." Brandhofer M, Hoffmann A, Blanchet X, Siminkovitch E, Rohlfing AK, El Bounkari O, Nestele JA, Bild A, Kontos C, Hille K, Rohde V, Fröhlich A, Golemi J, Gokce O, Krammer C, Scheiermann P, Tsilimparis N, Sachs N, Kempf WE, Maegdefessel L, Otabil MK, Megens RTA, Ippel H, Koenen RR, Luo J, Engelmann B, Mayo KH, Gawaz M, Kapurniotu A, Weber C, von Hundelshausen P, Bernhagen J. Cell Mol Life Sci. 2022 Sep 12;79(10):512. doi: 10.1007/s00018-022-04539-0.
  5. ​​​​​​"Designed peptides as nanomolar cross-amyloid inhibitors acting via supramolecular nanofiber co-assembly." Taş K, Dalla Volta  B, Lindner C, El Bounkari O, Hille K, Tian Y, Puig-Bosch X, Ballmann M, Hornung S, Ortner M, Prem S, Meier L, Rammes G, Haslbeck M, Weber C, Megens RTA, Bernhagen J, Kapurniotu A. Nature Communications (2022) 13(1):5004. doi: 10.1038/s41467-022-32688-0.
  6. “Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting.” Kontos C, El Bounkari O, Krammer C, Sinitski D, Hille K, Zan C, Yan G, Wang S, Gao Y, Brandhofer M, Megens RTA, Hoffmann A, Pauli J, Asare Y, Gerra S, Bourilhon P, Leng L, Eckstein H-H, Kempf WE, Pelisek J, Gokce O, Maegdefessel L, Bucala R, Dichgans M, Weber C, Kapurniotu A*, Bernhagen J*. Nature Communications (2020) 11(1):5981. doi:10.1038/s41467-020-19764-z.
  7. „A MIF-derived cyclopeptide that inhibits MIF binding and atherogenic signaling via the chemokine receptor CXCR2.” Krammer C., Kontos C., Dewor M. Hille K, Dalla Volta B., El Bounkari O, Taş K, Sinitski D, Brandhofer M, Megens RTA, Weber C, Schultz JR, Bernhagen J*, Kapurniotu A*. Chembiochem. (2021) 22(6):1012-1019. doi: 10.1002/cbic.202000574.
  8. "Enlightening amyloid fibrils linked to type 2 diabetes and cross-interactions with Abeta." Kapurniotu A. Nat Struct Mol Biol. (2020) 27(11):1006-1008. doi: 10.1038/s41594-020-00523-z.
  9. "The human cathelicidin LL-37 is a nanomolar inhibitor of amyloid self-assembly of islet amyloid polypeptide (IAPP)." Armiento V, Hille K, Naltsas D, Lin JS, Barron AE, Kapurniotu A. Angew Chem Int Ed Engl. (2020), 59(31):12837-12841. doi: 10.1002/anie.202000148.
  10. "Structural Insight into IAPP-Derived Amyloid Inhibitors and Their Mechanism of Action." Niu Z, Prade E, Malideli E, Hille K, Jussupow A, Mideksa YG, Yan LM, Qian C, Fleisch M, Messias AC, Sarkar R, Sattler M, Lamb DC, Feige MJ, Camilloni C, Kapurniotu A*, Reif B*. Angew Chem Int Ed Engl. (2020) 59(14):5771-5781. doi: 10.1002/anie.201914559.
  11. "Cross-kingdom mimicry of the receptor signaling and leukocyte recruitment activity of a human cytokine by its plant orthologs." Sinitski D, Gruner K, Brandhofer M, Kontos C, Winkler P, Reinstädler A, Bourilhon P, Xiao Z, Cool R, Kapurniotu A, Dekker FJ, Panstruga R, Bernhagen J. J Biol Chem. (2020) 295(3):850-867. doi: 10.1074/jbc.RA119.009716.
  12. "Peptide-based molecular strategies to interfere with protein misfolding, aggregation, and cell degeneration." Armiento V, Spanopoulou A, Kapurniotu A. Angew Chem Int Ed Engl. (2020) 59(9):3372-3384. doi: 10.1002/anie.201906908.
  13. "Blocking Inflammasome Activation Caused by beta-Amyloid Peptide (Abeta) and Islet Amyloid Polypeptide (IAPP) through an IAPP Mimic." Aftabizadeh M, Tatarek-Nossol M, Andreetto E, El Bounkari O, Kipp M, Beyer C, Latz E, Bernhagen J*, Kapurniotu A*. ACS Chem Neurosci. (201910) (8):3703-3717. doi: 10.1021/acschemneuro.9b00260.
  14. The Multitasking Potential of Alarmins and Atypical Chemokines.” Kapurniotu A, Gokce O, Bernhagen J. Front Med (Lausanne) 23;6:3 (2019). 
  15.  “Macrophage Migration Inhibitory Factor (MIF)-Based Therapeutic Concepts in Atherosclerosis and Inflammation.” Sinitski D, Kontos C, Krammer C, Asare Y, Kapurniotu A*, Bernhagen J*. Thromb Haemost. 119, 553-566 (2019).
  16. “Designed macrocyclic peptides as Nanomolar Amyloid Inhibitors Based on Minimal Recognition Elements”. Spanopoulou A., Heidrich L., Chen H.-R., Frost C., Hrle D., Malideli E., Hille K., Grammatikopoulos A., Bernhagen J., Zacharias M., Rammes G., Kapurniotu A., Angew. Chem. Int. Ed. 57, 14503-14508 (2018).
  17. "Identification of an Arg-Leu-Arg tripeptide that contributes to the binding interface between the cytokine MIF and the chemokine receptor CXCR4". Lacy M, Kontos C, Brandhofer M, Hille K, Gröning S, Sinitski D, Bourilhon P, Rosenberg E, Krammer C, Thavayogarajah T, Pantouris G, Bakou M, Weber C, Lolis E, Bernhagen J*, Kapurniotu A*. Sci. Rep. 8, 5171-87 (2018).
  18. "Mif-deficiency favors an atheroprotective autoantibody phenotype in atherosclerosis". Schmitz C, Noels H, El Bounkari O, Straussfeld E, Megens RTA, Sternkopf M, Alampour-Rajabi S, Krammer C, Tilstam PV, Gerdes N, Bürger C, Kapurniotu A, Bucala R, Jankowski J, Weber C, Bernhagen J. FASEB J. 32, 4428-4443 (2018).
  19. "LPS-mediated cell surface expression of CD74 promotes the profileration of B cells in response to MIF". Klasen C, Ziehm T, Huber M, Asare Y, Kapurniotu A, Shachar I, Bernhagen J, El Bounkari O. Cell Signal 46, 32-42 (2018). 
  20. "Key aromatic/hydrophobic amino acids controlling a cross-amyloid peptide interaction versus amyloid self-assembly". Bakou M, Hille K, Kracklauer M, Spanopoulou A, Frost CV, Malideli E, Yan LM, Caporale A, Zacharias M, Kapurniotu A. J. Biol. Chem. 292, 14587-602 (2017).
  21. "Peptide Inhibitors of the Amyloidogenesis of IAPP: Verification of the Hairpin Binding Geometry Hypothesis". Sivanesam K, Shu I, Huggins KN, Tatarek-Nossol M, Kapurniotu A, Andersen NH, FEBS Lett, 16, 2575-83 (2016).
  22. "Macrophage Migration Inhibitory Factor-CXCR4 Receptor Interactions: Evidence for Partial Allosteric Agonism in Comparison to CXCL12". Rajasekaran D, Gröning S, Schmitz C, Zierow S, Drucker N, Bakou M, Kohl K, Mertens A, Lue H, Weber C, Xiao A, Luker G, Kapurniotu A*, Lolis EJ*, Bernhagen J*, J. Biol. Chem. 291, 15881-95 (2016).
  23. "A Hot-Segment-Based Approach for the Design of Cross-Amyloid Interaction Surface Mimics as Inhibitors of Amyloid Self-Assembly". Andreetto E, Malideli E, Yan LM, Kracklauer M, Farbiarz K, Tatarek-Nossol M, Rammes G, Prade E, Neumüller T, Caporale A, Spanopoulou A, Bakou M, Reif B, Kapurniotu A, Angew Chem Int Ed Engl. 54, 13095-100 (2015). 
  24. "Development of Accessible Peptidic Tool Compounds To Study the Phosphatase PTP1B in Intact Cells". Meyer C, Hoeger B, Temmerman K, Tatarek-Nossol M, Pogenberg V, Bernhagen J, Wilmanns M, Kapurniotu A, Köhn M., ACS Chem Biol. 21, 769-76 (2014).
  25. „Molecular Characterization of the Hetero-Assembly of beta-Amyloid Peptide with Islet Amyloid Polypeptide”. Yan LM, Velkova A, Kapurniotu A., Curr Pharm Des. 20, 1182-91 (2014).
  26. „Selectively N-Methylated Soluble IAPP Mimics as Potent IAPP Receptor Agonists and Nanomolar Inhibitors of Cytotoxic Self-Assembly of Both IAPP and Abeta40”. Yan LM, Velkova A, Tatarek-Nossol M, Rammes G, Sibaev A, Andreetto E, Kracklauer M, Bakou M, Malideli E, Göke B, Schirra J, Storr M, Kapurniotu A., Angew Chem Int Ed Engl. 52, 10378-83 (2013).  
  27. "The backbone dynamics of the amyloid precursor protein transmembrane helix provides a rationale for the sequential cleavage mechanism of beta-secretase". Pester O, Barrett PJ, Hornburg D, Hornburg P, Pröbstle R, Widmaier S, Kutzner C, Dürrbaum M, Kapurniotu A, Sanders CR, Scharnagl C, Langosch D., J Am Chem Soc. 135, 1317-29 (2013).
  28. "Cross-Amyloid Interaction of Aß and IAPP at Lipid Membranes". Seeliger J, Evers F, Jeworrek C, Kapoor S, Weise K, Andreetto E, Tolan M, Kapurniotu A., Winter R. Angew. Chem. Int. Ed. Engl. 51, 679-83 (2012). 
  29. "Shedding light on Alzheimer`s ß-amyloid aggregation with chemical tools". Kapurniotu A., Chembiochem. 13, 27-9 (2012).
  30. "Terminating the amyloid zipper by design". Kapurniotu A., Angew Chem Int Ed Engl. 50, 11293-4 (2011).
  31. "Designed hairpin peptides interfere with amyloidogenesis pathways: fibril formation and cytotoxity inhibition, interception of the preamyloid state". Huggins KN, Bisaglia M, Bubacco L, Tatarek-Nossol M, Kapurniotu A., Andersen NH. Biochemistry. 50, 8202-12 (2011). 
  32. "Interaction between amyloid beta peptide and an aggregation blocker peptide mimicking islet amyloid polypeptide". Rezaei-Ghaleh N, Andreetto E, Yan LM, Kapurniotu A., Zweckstetter M. PLoS One. 6, 20289 (2011).
  33. "Dissecting the role of single regions of an IAPP mimic and IAPP in inhibition of Abeta40 amyloid formation and cytotoxicity." Andreetto, E., Yan, L-M., Caporale, A., Kapurniotu A.; ChemBioChem. 12, 1313-22, (2011).
  34. "MIF-chemokine receptor interactions in atherogenesis are dependent on an N-loop-based 2-site binding mechanism." Kraemer S, Lue H, Zernecke A, Kapurniotu A, Andreetto E, Frank R, Lennartz B, Weber C, Bernhagen J., FASEB J. 25, 894-906 (2011). 
  35. "Identification of Hot Regions of the Abeta-IAPP Interaction Interface As High Affinity Binding Sites in both Cross- and Self-Association" Erika Andreetto, Li-Mei Yan, Marianna Tatarek-Nossol, Aleksandra Velkova, Ronald Frank, A. Kapurniotu, Angew Chem Int Ed Engl. 49, 3081-3085 (2010).
  36. "Suppression of IAPP fibrillation at anionic lipid membranes via IAPP-derived amyloid inhibitors and insulin" D. Sellin, L.-M.Yan, A. Kapurniotu, R.Winter, Biophys. Chem. 150, 73-79 (2010). 
  37. “Exploiting Cross-Amyloid Interactions to Inhibit Protein Aggregation but not Function: Nanomolar Affinity Inhibition of Insulin Aggregation by an IAPP mimic” A. Velkova, M. Tatarek-Nossol, E. Andreetto, A. Kapurniotu Angew Chem Int Ed Engl. 47, 7114-7118 (2008).
  38. “Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte reqruitment” C. Weber, S. Kraemer, M. Drechsler, H. Lui, R. Koenen, A. Kapurniotu, A. Zernecke, J. Bernhagen Proc. Natl. Acad. Sci. USA 105, 16278-16283 (2008).
  39. “Cytotoxicity of Insulin within its Self-assembly and Amyloidogenic Pathways” S. Grudzielanek, A. Velkova, A. Shukla, V. Smirnovas, M. Tatarek-Nossol, H. Rehage, A. Kapurniotu, Winter R. J. Mol. Biol., 370, 372-84 (2007).
  40. “Designed IAPP Mimic Blocks Ab Cytotoxic Self-Assembly: Cross-Suppression of Amyloid Toxicity of Ab and IAPP Suggests a Molecular Link between Alzheimer’s Disease and Type 2 Diabetes” L.-M. Yan, A. Velkova, M. Tatarek-Nossol, E. Andreetto, A. Kapurniotu Angew Chem Int Ed Engl. VIP 46, 1246-1252 (2007).
  41. “Design of a mimic of non-amyloidogenic and bioactive IAPP as a nanomolar affinity inhibitor of IAPP fibrillogenesis and cytotoxicity” L.-M. Yan, M. Tatarek-Nossol, A. Velkova, A. Kazantzis, A. Kapurniotu Proc. Natl. Acad. Sci. USA, 103, 2046-2051 (2006).
  42. "A novel drug-eluting stent coated with an integrin-binding cRGD peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells" R. Blindt, F. Vogt, I. Astafieva, C. Fach, N. Krott, B. Seitz,  A. Kapurniotu, C. Kwok, M. Dewor, M. Hristov,  A. Bosserhoff,  J. Bernhagen, P. Hanrath, R. Hoffmann, C. Weber J. Am. Coll. Cardiol. 47, 1786-95 (2006). 
  43. “Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity” H. Lue, A. Kapurniotu, G. Fingerle-Rowson, T. Roger, L. Leng, M. Thiele, T. Calandra, R. Bucala, J. Bernhagen Cell Signal., 18, 688-703 (2005).
  44. “Macrophage migration inhibitory factor (MIF) increases neuronal delayed rectifier K+ current” T. Matsuura, C. Sun, L. Leng, A. Kapurniotu, J. Bernhagen, R. Bucala, A. E. Martynyuk, C. Sumners J. Neurophysiol., 95, 1042-1048 (2005).
  45. “Inhibition of IAPP amyloid fibril formation and apoptotic cell death by a designed IAPP amyloid core-containing hexapeptide”, M. Tatarek-Nossol, L.M. Yan, A. Schmauder, K. Tenidis, G. Westermark A. Kapurniotu Chem. Biol., 12, 797-809 (2005).
  46. “Targeting a-synuclein in Parkinson’s disease”, A. Kapurniotu Chem. Biol., 11, 1476-77 (2004).
  47. “Contribution of conformationally constrained calcitonin analogues to the understanding of the structural and conformational requirements of calcitonin bioactivity and to the design of potent agonists”, A. Kapurniotu Curr. Med. Chem., 11, 2577-97 (2004) (Review).
  48. “A sixteen residue peptide fragment of macrophage migration inhibitory factor, MIF(50-65), exhibits redox activity and has MIF-like biological functions”, M. T. Nguyen, J. Beck, H. Lue, R. Kleemann, P. Koolwijk, A. Kapurniotu, J. Bernhagen. J. Biol. Chem. 278, 33654-71 (2003).
  49. “Conformational restriction via cyclization in b-amyloid peptide Abeta(1-28) leads to an inhibitor of Aß(1-28) amyloidogenesis and cytotoxicity”, A. Kapurniotu, A. Buck, M. Weber, A. Schmauder, T. Hirsch, J. Bernhagen, M. Tatarek-Nossol. Chem. Biol. 10, 149-159 (2003).
  50. "Structure-based design and study of non-amyloidogenic, double N-methylated IAPP amyloid core sequences as inhibitors of IAPP amyloid formation and cytotoxicity”, A. Kapurniotu, A. Schmauder, K. Tenidis. J. Mol. Biol., 315, 339-350 (2002).
  51. „Side-chain lactam-bridge conformational constrains differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues“, J. W. Taylor, Q. K. Jin, M. Sbacchi, L. Wang, P. Belfiore, M. Garnier, A. Kazantzis, A. Kapurniotu, P. F. Zaratin, M. A. Scheideler. J. Med. Chem., 45, 1108-1121 (2002). 
  52. „Conformationally constrained human calcitonin (hCt) analogues reveal a critical role of sequence 17-21 for the oligomerization state and bioactivity of hCt“, A. Kazantzis, M. Waldner, J. W. Taylor, A. Kapurniotu. Eur. J. Biochem., 269, 780-791 (2002).
  53. „Amyloidogenicity and cytotoxicity of islet amyloid polypeptide (IAPP)“, A. Kapurniotu. Biopolymers, 60, 438-59 (2001) (Review).
  54. „Amyloidogenicity of recombinant human pro-islet amyloid polypeptide (ProIAPP)“, M. Krampert, J. Bernhagen, J. Schmucker, A. Horn, A. Schmauder, H. Brunner, W. Voelter, & A. Kapurniotu. Chem. Biol., 7, 855-871 (2000).
  55. „Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1“, R. Kleemann, A. Hausser, G. Geiger, R. Mischke, A. Burger-Kentischer, O. Flieger, F.-J. Johannes, T. Roger, T. Calandra, A. Kapurniotu, M. Grell, D. Finkelmeier, H. Brunner, & J. Bernhagen. Nature, 408, 211-216 (2000).
  56. „Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor (MIF) production in monocytes“, M. Schmidt-Supprian, C. Murphy, B. White, M. Lawler, A. Kapurniotu, W. Voelter, O. Smith, J. Bernhagen. Eur. Cytokine Netw., 11, 3 (2000).
  57. „Identification of a Penta- and Hexapeptide of Islet Amyloid Polypeptide (IAPP) with Amyloidogenic and Cytotoxic Properties“, K. Tenidis, M. Waldner, J. Bernhagen, W. Fischle, M. Bergmann, M. Weber, M.-L. Merkle, W. Voelter, H. Brunner, A. Kapurniotu, J. Mol. Biol., 295, 1055-1071 (2000).
  58. „Rational design, confomational studies and bioactivity of novel, highly potent, conformationally constrained calcitonin analogues“, A. Kapurniotu, R. Kayed, J. W. Taylor, W. Voelter, Eur. J. Biochem., 265, 606-618 (1999).
  59. "Advanced glycation end products in deposited proteins: detection and reversal“, Y. Al-Abed, A. Kapurniotu, R. Bucala, Methods Enzymol., 309, 152-72 (1999) (Review).
  60. „Characterization of catalytic center mutants of macrophage migration inhibitory factor (MIF) and comparison to C81S MIF“, R. Kleemann, A. Kapurniotu, R. Mischke, J. Held, J. Bernhagen, Eur. J. Biochem., 261, 753-766 (1999).
  61. „Conformational transitions of islet amyloid polypeptide in amyloid formation in vitro“ R. Kayed, J. Bernhagen, N. Greenfield, K. Sweimeh, H. Brunner, W. Voelter, A. Kapurniotu, J. Mol. Biol., 287, 781-796 (1999).
  62. „Model studies of the Maillard reaction of Arg-Lys with D-glucose“, Y.Al-Abed, D. Callaway, A. Kapurniotu, T. Holak, W. Voelter, R. Bucala, Polisch J. Chem., 73, 117-123 (1999).
  63. „Specific reduction of insulin disulfides by macrophage migration inhibitory factor (MIF) with glutathione and dihydrolipoamide: potential role in cellular redox processes“, R. Kleemann, R. Mischke, A. Kapurniotu, H. Brunner, J. Bernhagen, FEBS Lett., 430, 191-196 (1998).
  64. „Disulfide Analysis Reveals a Role for Macrophage Migration Inhibitory Factor (MIF) as Thiol-protein Oxidoreductase“, R. Kleemann, A. Kapurniotu, R. W. Frank, A. Gessner, R. Mischke, S. Jüttner, H. Brunner, J. Bernhagen., J. Mol. Biol., 280, 85-102 (1998).
  65. „Contribution of advanced glycosylation to the amyloidogenicity of islet amyloid polypeptide (IAPP)“, A. Kapurniotu, J. Bernhagen, N. Greenfield, S. Teichberg, R.W. Frank, Y. Al-Abed, R. Bucala, Eur. J. Biochem., 251, 208-216 (1998).

 -- publications since 1998
* co-corresponding author 

To top